Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Intestinal Diseases × alvimopan × Clear all

Phase

Phase 3 3 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Constipation 2 Peritoneal Neoplasms 1 Opioid-Induced Constipation 1 Intestinal Diseases 1 Ileus 1

Interventions

pembrolizumab 1 alvimopan 1 Oxaliplatin 1 Ocoxin 1 Cyclophosphamide 1 Chemoradiotherapy 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00135577 2015-09-02

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed

Opioid-Induced Constipation, Constipation, Intestinal Diseases, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡